Bright Minds Biosciences Statistics
Total Valuation
DRUG has a market cap or net worth of $721.39 million. The enterprise value is $499.88 million.
| Market Cap | 721.39M |
| Enterprise Value | 499.88M |
Important Dates
The last earnings date was Monday, August 17, 2026, before market open.
| Earnings Date | Aug 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DRUG has 9.86 million shares outstanding. The number of shares has increased by 38.94% in one year.
| Current Share Class | 9.86M |
| Shares Outstanding | 9.86M |
| Shares Change (YoY) | +38.94% |
| Shares Change (QoQ) | +2.51% |
| Owned by Insiders (%) | 16.73% |
| Owned by Institutions (%) | 74.50% |
| Float | 6.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.33 |
| P/TBV Ratio | 3.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 121.97, with a Debt / Equity ratio of 0.00.
| Current Ratio | 121.97 |
| Quick Ratio | 121.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -753.50 |
Financial Efficiency
Return on equity (ROE) is -13.63% and return on invested capital (ROIC) is -13.61%.
| Return on Equity (ROE) | -13.63% |
| Return on Assets (ROA) | -13.50% |
| Return on Invested Capital (ROIC) | -13.61% |
| Return on Capital Employed (ROCE) | -12.73% |
| Weighted Average Cost of Capital (WACC) | 4.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$663,789 |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +67.92% in the last 52 weeks. The beta is 0.09, so DRUG's price volatility has been lower than the market average.
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +67.92% |
| 50-Day Moving Average | 73.91 |
| 200-Day Moving Average | 77.59 |
| Relative Strength Index (RSI) | 42.51 |
| Average Volume (20 Days) | 150,864 |
Short Selling Information
The latest short interest is 897,280, so 9.10% of the outstanding shares have been sold short.
| Short Interest | 897,280 |
| Short Previous Month | 890,847 |
| Short % of Shares Out | 9.10% |
| Short % of Float | 14.45% |
| Short Ratio (days to cover) | 4.43 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.59M |
| Pretax Income | -17.26M |
| Net Income | -17.26M |
| EBITDA | n/a |
| EBIT | -27.59M |
| Earnings Per Share (EPS) | -$2.01 |
Balance Sheet
The company has $216.77 million in cash and $46,186 in debt, with a net cash position of $216.72 million or $21.97 per share.
| Cash & Cash Equivalents | 216.77M |
| Total Debt | 46,186 |
| Net Cash | 216.72M |
| Net Cash Per Share | $21.97 |
| Equity (Book Value) | 216.74M |
| Book Value Per Share | 21.97 |
| Working Capital | 216.70M |
Cash Flow
| Operating Cash Flow | -17.73M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 54,668 |
| Net Borrowing | -75,307 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRUG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.94% |
| Shareholder Yield | -38.94% |
| Earnings Yield | -2.39% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DRUG is $170.11, which is 133.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $170.11 |
| Price Target Difference | 133.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 14, 2023. It was a reverse split with a ratio of 1:5.
| Last Split Date | Jul 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |